Antitumor activity of BRAF inhibitor and IFN×alpha; Combination in BRAF-mutant melanoma

Journal of the National Cancer Institute

Volumn 108, Issue 7, 2016, Pages

  Sabbatino, Francesco ^a   Wang, Yangyang ^a   Scognamiglio, Giosue ^b   Favoino, Elvira ^a,g   Feldman, Steven A ^c   Villani, Vincenzo ^a   Flaherty, Keith T ^a   Nota, Sjoerd ^a   Giannarelli, Diana ^d   Simeone, Ester ^b   Anniciello, Anna M ^b   Palmieri, Giuseppe ^e   Pepe, Stefano ^f   Botti, Gerardo ^b   Ascierto, Paolo A ^b   Ferrone, Cristina R ^a   Ferrone, Soldano ^a,f  

^a HARVARD MEDICAL SCHOOL   (United States)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c NATIONAL CANCER INSTITUTE   (United States)

^d REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^e CNR   (Italy)

^f UNIVERSITY OF SALERNO   (Italy)

^g NATIONAL INSTITUTE FOR DIGESTIVE DISEASES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON RECEPTOR; ALPHA2B INTERFERON; B RAF KINASE; B RAF KINASE INHIBITOR; CALNEXIN; CALRETICULIN; GENOMIC DNA; HLA ANTIGEN CLASS 1; HLA DP ANTIGEN; HLA DQ ANTIGEN; HLA DR ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; MELAN A; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; PROTEOCHONDROITIN SULFATE; STAT1 PROTEIN; STAT2 PROTEIN; STAT3 PROTEIN; VEMURAFENIB; ALPHA BETA INTERFERON RECEPTOR; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BRAF PROTEIN, HUMAN; GLUTAMIC ACID; IFNAR1 PROTEIN, HUMAN; VALINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; FEMALE; GENOTYPE; HUMAN; HUMAN CELL; MELANOMA; MOUSE; NONHUMAN; ONCOGENE N RAS; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; UPREGULATION; WESTERN BLOTTING; WILD TYPE; ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CELL PROLIFERATION; DRUG EFFECTS; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; MUTATION; NONOBESE DIABETIC MOUSE; SCID MOUSE; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUTAMIC ACID; HUMANS; IMMUNOHISTOCHEMISTRY; INTERFERON-ALPHA; MAP KINASE SIGNALING SYSTEM; MELANOMA; MICE; MICE, INBRED NOD; MICE, SCID; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; RECEPTOR, INTERFERON ALPHA-BETA; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; VALINE;

EID: 84979270657     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djv435     Document Type: Article

References (38)

1. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507-2516.
2. Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380(9839):358-365.
3. McArthur GA, Chapman PB, Robert C, et al. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol. 2014;15(3):323-332.
4. Wan PT, Garnett MJ, Roe SM, et al. Mechanism of activation of the RAFERK signaling pathway by oncogenic mutations of B-RAF. Cell. 2004;116(6): 855-867.
5. Cohen C, Zavala-Pompa A, Sequeira JH, et al. Mitogen-actived protein kinase activation is an early event in melanoma progression. Clin Cancer Res. 2002;8(12):3728-3733.
6. Sapkota B, Hill CE, Pollack BP. Vemurafenib enhances MHC induction in BRAF homozygous melanoma cells. Oncoimmunology. 2013;2(1):e22890.
7. Boni A, Cogdill AP, Dang P, et al. Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. Cancer Res. 2010;70(13):5213-5219.
8. Mimura K, Kua LF, Shiraishi K, et al. Inhibition of mitogen-activated protein kinase pathway can induce upregulation of human leukocyte antigen class I without PD-L1-upregulation in contrast to interferon-gamma treatment. Cancer Sci. 2014;105(10):1236-1244.
9. Frederick DT, Piris A, Cogdill AP, et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res. 2013;19(5):1225-1231.
10. Liu J, Suresh Kumar KG, Yu D, et al. Oncogenic BRAF regulates beta-Trcp expression and NF-kappaB activity in human melanoma cells. Oncogene. 2007;26(13):1954-1958.
11. Taniguchi T, Takaoka A. A weak signal for strong responses: interferonalpha/ beta revisited. Nat Rev Mol Cell Biol. 2001;2(5):378-386.
12. Colamonici OR, Porterfield B, Domanski P, et al. Ligand-independent antioncogenic activity of the alpha subunit of the type I interferon receptor. J Biol Chem. 1994;269(44):27275-27279.
13. Mocellin S, Pasquali S, Rossi CR, et al. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Natl Cancer Inst. 2010;102(7):493-501.
14. Spiegelman VS, Tang W, Chan AM, et al. Induction of homologue of Slimb ubiquitin ligase receptor by mitogen signaling. J Biol Chem. 2002;277(39): 36624-36630.
15. Kumar KG, Tang W, Ravindranath AK, et al. SCF(HOS) ubiquitin ligase mediates the ligand-induced down-regulation of the interferon-alpha receptor. EMBO J. 2003;22(20):5480-5490.
16. Lee JH, Choi JW, Kim YS. Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis. Br J Dermatol. 2011;164(4):776-784.
17. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949-954.
18. Colombino M, Capone M, Lissia A, et al. BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. J Clin Oncol. 2012;30(20):2522-2529.
19. Wang X, Osada T, Wang Y, et al. CSPG4 protein as a new target for the antibody- based immunotherapy of triple-negative breast cancer. J Natl Cancer Inst. 2010;102(19):1496-1512.
20. Ogino T, Wang X, Ferrone S. Modified flow cytometry and cell-ELISA methodology to detect HLA class I antigen processing machinery components in cytoplasm and endoplasmic reticulum. J Immunol Methods. 2003;278(1-2):33-44.
21. Vermes I, Haanen C, Steffens-Nakken H, et al. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods. 1995;184(1):39-51.
22. Sabbatino F, Wang Y, Wang X, et al. PDGFRalpha up-regulation mediated by sonic hedgehog pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutation. Oncotarget. 2014;5(7):1926-1941.
23. Robbins PF, Li YF, El-Gamil M, et al. Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions. J Immunol. 2008;180(9):6116-6131.
24. Zhao Y, Wang QJ, Yang S, et al. A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity. J Immunol. 2009;183(9):5563-5574.
25. Williams BR. Transcriptional regulation of interferon-stimulated genes. Eur J Biochem. 1991;200(1):1-11.
26. Angell TE, Lechner MG, Jang JK, et al. MHC Class I Loss is a Frequent Mechanism of Immune Escape in Papillary Thyroid Cancer that is Reversed by Interferon and Selumetinib Treatment in vitro. Clin Cancer Res. 2014;20(23):6034-6044.
27. Garbe C, Krasagakis K, Zouboulis CC, et al. Antitumor activities of interferon alpha, beta, and gamma and their combinations on human melanoma cells in vitro: changes of proliferation, melanin synthesis, and immunophenotype. J Invest Dermatol. 1990;95(6 Suppl):231S-237S.
28. Nistico P, Tecce R, Giacomini P, et al. Effect of recombinant human leukocyte, fibroblast, and immune interferons on expression of class I and II major histocompatibility complex and invariant chain in early passage human melanoma cells. Cancer Res. 1990;50(23):7422-7429.
29. Maio M, Gulwani B, Langer JA, et al. Modulation by interferons of HLA antigen, high-molecular-weight melanoma associated antigen, and intercellular adhesion molecule 1 expression by cultured melanoma cells with different metastatic potential. Cancer Res. 1989;49(11):2980-2987.
30. Greiner JW, Guadagni F, Noguchi P, et al. Recombinant interferon enhances monoclonal antibody-targeting of carcinoma lesions in vivo. Science. 1987;235(4791):895-898.
31. Mimura K, Shiraishi K, Mueller A, et al. The MAPK pathway is a predominant regulator of HLA-A expression in esophageal and gastric cancer. J Immunol. 2013;191(12):6261-6272.
32. Caraglia M, Dicitore A, Marra M, et al. Type I interferons: ancient peptides with still under-discovered anti-cancer properties. Protein Pept Lett. 2013;20(4):412-423.
33. Darnell JE, Jr., Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science. 1994;264(5164):1415-1421.
34. Bruzzese F, Di Gennaro E, Avallone A, et al. Synergistic antitumor activity of epidermal growth factor receptor tyrosine kinase inhibitor gefitinib and IFN-alpha in head and neck cancer cells in vitro and in vivo. Clin Cancer Res. 2006;12(2):617-625.
35. Caraglia M, Marra M, Viscomi C, et al. The farnesyltransferase inhibitor R115777 (ZARNESTRA) enhances the pro-apoptotic activity of interferonalpha through the inhibition of multiple survival pathways. Int J Cancer. 2007;121(10):2317-2330.
36. Dietrich A, Tanczos E, Vanscheidt W, et al. High CD44 surface expression on primary tumours of malignant melanoma correlates with increased metastatic risk and reduced survival. Eur J Cancer. 1997;33(6):926-930.
37. Larkin J, Ascierto PA, Dreno B, et al. Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma. N Engl J Med. 2014;371(20):1867-1876.
38. Long GV, Stroyakovskiy D, Gogas H, et al. Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma. N Engl J Med. 2014;371(20):1877-1888.